Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

We are a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases.

Our chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. Our pipeline is initially focused on neurological disorders and extends across several other therapeutic areas.

1st

first to design and bring stereopure and allele-specific medicines to clinic

6

neurology development
programs by end of 2018

3

clinical studies
initiated in 2017

5

nucleic acid modalities being advanced with Wave stereopure chemistry

12+

discovery programs

5

therapeutic areas under active investigation

 

Investor Relations

Recent News

May 07, 2018

Wave Life Sciences Highlights Progress on Hepatic Collaboration with Pfizer

With the designation of five targets, Pfizer nominates the maximum permitted under collaboration Collaboration moving toward candidate selection CAMBRIDGE, Mass. , May 07, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational

Events

Recent News

May 07, 2018

Wave Life Sciences Highlights Progress on Hepatic Collaboration with Pfizer

With the designation of five targets, Pfizer nominates the maximum permitted under collaboration Collaboration moving toward candidate selection CAMBRIDGE, Mass. , May 07, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a biotechnology company focused on delivering transformational

Recent News and Events

Copyright Nasdaq. Minimum 15 minutes delayed.